The DOI matches its Crossref record.
Prevention of Diabetic Vascular Dysfunction by Guanidines: Inhibition of Nitric Oxide Synthase Versus Advanced Glycation End-Product Formation
Abstract
This study was undertaken to compare the ability of two guanidine compounds (aminoguanidine and methylguanidine), with different in vitro effects on NO synthase activity and AGE formation, to inhibit diabetic vascular dysfunction developing early after the onset of diabetes. In rats with STZ-induced diabetes of 5-wk duration, regional vascular [125I]albumin permeation was increased about two- to threefold in ocular tissues, sciatic nerve, and aorta; in general, both guanidine compounds normalized albumin permeation in diabetic rats without affecting it in controls. Methylguanidine was only ∼7% as effective as aminoguanidine as an inhibitor of AGE formation from L-lysine and G6P; both compounds were poor inhibitors of AR. Methylguanidine was ∼1–5% as potent as aminoguanidine and L-NMMA as an inhibitor of the cytokine- and endotoxin-inducible isoform of NO synthase. In contrast, the potency of methylguanidine as an inhibitor of the constitutive isoform of NO synthase was comparable to that of aminoguanidine, and both guanidine compounds were much less effective than L-NMMA. These observations suggest a role for a relative or absolute increase in NO production in the pathogenesis of early diabetic vascular dysfunction and raise the possibility that inhibition of diabetic vascular functional changes by aminoguanidine may reflect inhibition of NO synthase activity rather than, or in addition to, prevention of AGE formation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Endothelial dysfunction in diabetes
De Vriese, A. S., Verbeuren, T. J., Van de Voorde, J., Lameire, N. H., & Vanhoutte, P. M. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703393 · Cited by 1,165
Hyperglycemic Pseudohypoxia and Diabetic Complications
Williamson, J. R., Chang, K., Frangos, M., Hasan, K. S., Ido, Y., Kawamura, T., Nyengaard, J. R., Den Enden, M. V., Kilo, C., & Tilton, R. G. (1993) · Diabetes · doi:10.2337/diab.42.6.801 · Cited by 1,105
Self-citationMiyamoto, K., Khosrof, S., Bursell, S.-E., Rohan, R., Murata, T., Clermont, A. C., Aiello, L. P., Ogura, Y., & Adamis, A. P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.19.10836 · Cited by 788
Selective pharmacological inhibition of distinct nitric oxide synthase isoforms
Southan, G. J., & Szabó, C. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02099-3 · Cited by 569
Diabetic Microvascular Disease: An Endocrine Society Scientific Statement
Barrett, E. J., Liu, Z., Khamaisi, M., King, G. L., Klein, R., Klein, B. E. K., Hughes, T. M., Craft, S., Freedman, B. I., Bowden, D. W., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01922 · Cited by 515
Abnormalities of Retinal Metabolism in Diabetes and Experimental Galactosemia
Kowluru, R. A., Tang, J., & Kern, T. S. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1938 · Cited by 435
Szabó, C., Southan, G. J., & Thiemermann, C. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12472 · Cited by 406
Topical and systemic drug delivery to the posterior segments
HUGHES, P., OLEJNIK, O., CHANGLIN, J., & WILSON, C. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.004 · Cited by 400
Aminoguanidine selectively inhibits inducible nitric oxide synthase
Griffiths, M. J. D., Messent, M., MacAllister, R. J., & Evans, T. W. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb13907.x · Cited by 397
Pieper, G. M. (1998) · Hypertension · doi:10.1161/01.hyp.31.5.1047 · Cited by 355
The Pathogenesis of Edema in Diabetic Maculopathy
Antcliff, R. J., & Marshall, J. (1999) · Seminars in Ophthalmology · doi:10.3109/08820539909069541 · Cited by 342
Chen, Y.-H., Lin, S.-J., Lin, M.-W., Tsai, H.-L., Kuo, S.-S., Chen, J.-W., Charng, M.-J., Wu, T.-C., Chen, L.-C., Ding, P., et al. (2002) · Human Genetics · doi:10.1007/s00439-002-0769-4 · Cited by 314
Nitric Oxide: A Review of Its Role in Retinal Function and Disease
GOLDSTEIN, I. M., OSTWALD, P., & ROTH, S. (1996) · Vision Research · doi:10.1016/0042-6989(96)00017-x · Cited by 313
Vascular dysfunction in diabetes mellitus
Feener, E. P., & King, G. L. (1997) · The Lancet · doi:10.1016/s0140-6736(97)90022-2 · Cited by 287
The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease
Cohen, R. A. (1995) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(05)80002-7 · Cited by 286
Role of the Maillard Reaction in Diabetes Mellitus and Diseases of Aging
Thorpe, S. R., & Baynes, J. W. (1996) · Drugs & Aging · doi:10.2165/00002512-199609020-00001 · Cited by 285
Kowluru, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.818 · Cited by 282
Pharmacological Inhibition of Diabetic Retinopathy
Kern, T. S., & Engerman, R. L. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1636 · Cited by 277
Forbes, J. M., Cooper, M. E., Thallas, V., Burns, W. C., Thomas, M. C., Brammar, G. C., Lee, F., Grant, S. L., Burrell, L. M., Jerums, G., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.11.3274 · Cited by 277
Takano, H., Manchikalapudi, S., Tang, X.-L., Qiu, Y., Rizvi, A., Jadoon, A. K., Zhang, Q., & Bolli, R. (1998) · Circulation · doi:10.1161/01.cir.98.5.441 · Cited by 256
Wendt, T., Tanji, N., Guo, J., Hudson, B. I., Bierhaus, A., Ramasamy, R., Arnold, B., Nawroth, P. P., Yan, S. F., D’Agati, V., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000065100.17349.ca · Cited by 239
Cameron, N. E., & Cotter, M. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118104 · Cited by 147
Metadata
- Authors
- Tilton, R. G., Chang, K., Hasan, K. S., Smith, S. R., Petrash, J. M., Misko, T. P., Moore, W. M., Currie, M. G., Corbett, J. A., McDaniel, M. L., & Williamson, J. R.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1993-02-01
- Volume
- 42
- Issue
- 2
- Pages
- 221-232
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2075100842
- Cited by
- 293
- References
- 0
- FWCI
- 20.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.